Based on current timelines, approval is projected for late 2026 to early 2027, with commercial availability likely in 2027
00:05:49 Vickie Danaher So if youre reading the clinical trial data or seeing this in parts of the package insert and you notice that the capsule doses dont seem to match the tablet versions on the shelf, thats why
Extrinsic rewards include earning virtual currency for healthy behavior
Patients in clinical studies experienced improvements in blood sugar control, reduced waist circumference, lower cholesterol levels, and reduced cardiovascular risks
[15] Potential GLP-1 Interactions According to research published by Liu and colleagues in 2014, green tea extract significantly increased glucagon-like peptide 1 (GLP-1) levels in patients with type 2 diabetes and lipid abnormalities, but only in the within-group comparison
$ 49.3 Bn GLP-1 Markets 2024-2035 with Boehringer Ingelheim, Eli Lilly, Novo Nordisk Dominating